AZ’s opportunity to expand the severe asthma market with tezepelumab

Phase III data from AstraZeneca and Amgen’s tezepelumab suggests the mAb could substantially expand the use of biologics in severe asthma beyond the subset of patients addressed by marketed therapies.

Asthma affects a huge population of about 340 million patients worldwide, and while most have mild to moderate disease that can be controlled with inhaled therapies, Pablo Panella, AstraZeneca’s SVP and global head of respiratory and immunology, told BioCentury that about 10% suffer from severe, uncontrolled disease that results in frequent exacerbations...